Literature DB >> 309951

Protease inhibitor profile of black Americans with and without chronic cardiopulmonary disease.

R C Young, V E Headings, A L Henderson, S Bose, R L Hackney.   

Abstract

An epidemiologic study of protease inhibitor (alpha(1)-antitrypsin) was undertaken among 599 ambulatory and hospitalized black American patients with chronic cardiopulmonary disease referred for pulmonary function testing, and 115 ethnically matched, healthy control subjects. Clinical evaluation consisted of respiratory questionnaire completion, physical examination, chest radiograph, and spirography. Protease inhibitor evaluation consisted of measurement of serum trypsin inhibitory capacity in all subjects corrected by comparison with control sera, while 200 of these subjects were phenotyped for alpha(1)-antitrypsin electrophoretic variants.Results showed mean serum trypsin inhibitory capacity for all subjects was 1.56, SD ± 0.47 mg/ml, while corrected values were 111.2, SD ± 30.5 percent of control. Acute phase reactivity was present for patients with heart disease, pulmonary malignancy, p<0.01 for both, and pulmonary fibrosis, p<0.05, when compared with controls. Prevalence of protease inhibitor variants in 29 controls was two heterozygotes for the Z variant (seven percent), and one homozygote for the S variant. Among 94 patients with chronic obstructive pulmonary disease, prevalence was 1.1 percent each for ZZ and SZ phenotypes, and 2.1 percent for MZ. Suprprisingly, the sole ZZ patient had asthmatic bronchitis rather than emphysema.Computed allele frequencies for Pi M and Z were comparable to those for a random sample of black Americans in St. Louis, but differed from a sample of black infants in Brooklyn, NY.These results indicate that protease inhibitor deficiency variants are not as uncommon among black Americans as the literature suggests. Furthermore, the heterozygous state is not necessarily a risk factor in development of chronic obstructive pulmonary disease. Protease inhibitor deficiency states therefore appear to play less important a role in etiology of chronic cardiopulmonary disease in black Americans than among their Caucasian counterparts.Preliminary work was published in abstract form.(1)

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309951      PMCID: PMC2537180     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  47 in total

1.  A preliminary report on a study of serum alpha-1-antitrypsin and immunoglobulin levels in lepromatous leprosy.

Authors:  S I Celikoğlu; F M Göksel; T Bilgin
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

2.  Comparison of questionnaires: the BMRC and NHLI respiratory questionnaires and a new self-completion questionnaire.

Authors:  M D Lebowitz; B Burrows
Journal:  Am Rev Respir Dis       Date:  1976-05

3.  Spirometric standards for healthy inner-city black children.

Authors:  M N Chehreh; R C Young; H Viaene; C W Ross; R B Scott
Journal:  Am J Dis Child       Date:  1973-08

4.  Alpha 1 -antitrypsin deficiency as an indicator of susceptibility to pulmonary disease.

Authors:  C Mittman; T Barbela; J Lieberman
Journal:  J Occup Med       Date:  1973-01

5.  Genetic and environmental determinants of chronic obstructive pulmonary disease.

Authors:  R K Larson; M L Barman; F Kueppers; H H Fudenberg
Journal:  Ann Intern Med       Date:  1970-05       Impact factor: 25.391

6.  Investigations on the population genetics of the alpha-1-antitrypsin polymorphism.

Authors:  G Kellermann; H Walter
Journal:  Humangenetik       Date:  1970-09-17

7.  Protease inhibitors in patients with chronic obstructive pulmonary disease: the alpha-antitrypsin heterozygote controversy.

Authors:  D W Cox; V H Hoeppner; H Levison
Journal:  Am Rev Respir Dis       Date:  1976-05

8.  Serum trypsin inhibitory capacity and pi phenotypes. II. Prevalence of alpha1-antitrypsin deficiency in an allergy population.

Authors:  J Ihrig; H J Schwartz; D J Rynbrandt; J Kleinerman
Journal:  Am J Clin Pathol       Date:  1975-09       Impact factor: 2.493

9.  A genetic-epidemiologic study of chronic obstructive pulmonary disease. I. Study design and preliminary observations.

Authors:  B H Cohen; W C Ball; W B Bias; S Brashears; G A Chase; E L Diamond; S H Hsu; P Kreiss; D A Levy; H A Menkes; S Permutt; M S Tockman
Journal:  Johns Hopkins Med J       Date:  1975-09

10.  Protease inhibitors in chronic obstructive pulmonary disease.

Authors:  T B Barnett; D Gottovi; A M Johnson
Journal:  Am Rev Respir Dis       Date:  1975-05
View more
  1 in total

Review 1.  Chronic obstructive pulmonary disease in blacks and whites: pulmonary function norms and risk factors.

Authors:  R F Gillum
Journal:  J Natl Med Assoc       Date:  1991-05       Impact factor: 1.798

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.